GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET...
Day: July 24, 2023
MDbio – The Doctors BrandTM Publishes New Article About Artificial Intelligence in Healthcare
Beverly Hills, California, July 24, 2023 (GLOBE NEWSWIRE) -- MDbio – The Doctors BrandTM published a new article about artificial intelligence...
Lytus Technologies enters Fintech space with the launch of a new payment gateway in India
~Will invest 50 million dollars to expand their fintech service in India over the next 5 years~ Mumbai | New...
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of...
ICU Medical Announces Time of Second Quarter 2023 Earnings Conference Call
SAN CLEMENTE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major...
Nanox Announces $30 Million Registered Direct Offering
NEVE ILAN, Israel, July 24, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative...
TOMI Announces Preliminary Second Quarter Revenue Growth of 90%
FREDERICK, Md., July 24, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty...
Qualigen Therapeutics Divests FastPack® Diagnostics Business
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority...
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical...
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ETCORAL GABLES, Fla., July...
SmileDirectClub Expands New Premium CarePlus Offering To All US SmileShops and Select Partner Network Locations
Premium Aligner Service Blends In-Person Doctor Visits And Virtual Check-Ins, Plus Concierge Customer Service and Elevated Product FeaturesNASHVILLE, Tenn., July...
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.Lyon...
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is...
DLH to Announce Fiscal 2023 Third Quarter Financial Results
ATLANTA, July 24, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and...
Applied UV’s Subsidiary, PURO, and Its Partner Academy Energy Group (AEG), Have Been Selected As a Finalist for the GSA’s Green Proving Ground (GPG) Program
Germicidal Ultraviolet, PURO with its Partner Academy Energy Group – Using next-generation LEDs and Far-UVC light to disinfect air without...
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase...
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition...
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
WESTON, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical...